Arab Finance: Minapharm Pharmaceuticals turned profitable in the first half (H1) of 2026, with EGP 102.247 million in consolidated net profit attributable to the owners, against net losses of EGP 220.436 million in H1 2025, the financial results showed.
Total revenues increased to EGP 4.095 billion at the end of June 2026 from EGP 3.338 billion a year earlier.
Basic and diluted earnings per share (EPS) reached EGP 7.72 when compared to a loss per share of EGP 20.95.
As for the standalone business, net profit hit EGP 101.82 million in H1 2026, against a net loss of EGP 222.22 million a year earlier. Meanwhile, sales rose to EGP 2.44 billion from EGP 1.92 billion.
